Company intelligence / Profile preview

Centre for Translational Stem Cell Biology

Ownership: Private
Development stage: Preclinical

Overview

CTSCB has established world-leading expertise in developing EPSC lines from multiple mammalian species including humans, mice, and pigs. Their work underpins new approaches in regenerative medicine, organ transplantation, genomic medicine of immune disease, drug discovery screening platforms, and universal donor cell development. No clinical trial results are reported yet.

Therapeutic areas: OtherRare DiseasesImmunology
Modalities: Expanded Potential Stem Cells (EPSCs)Induced Pluripotent Stem Cells (iPSC)Genomic medicine platforms
Industry: Academic Hospital/University/Research

Partnerships

The University of Hong Kong Li Ka Shing Faculty of Medicine (“HKUMed”)InnoHK@HKU / Health@INNOHK government innovation initiative partners

Beyond the preview

Go deeper on Centre for Translational Stem Cell Biology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Centre for Translational Stem Cell Biology.

Explore the full profile